These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 36747375)
1. Training the microbiota to increase immune checkpoint blockade and to reduce toxicity. Rescigno M Eur J Immunol; 2023 Nov; 53(11):e2250183. PubMed ID: 36747375 [TBL] [Abstract][Full Text] [Related]
2. Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients. Derosa L; Routy B; Fidelle M; Iebba V; Alla L; Pasolli E; Segata N; Desnoyer A; Pietrantonio F; Ferrere G; Fahrner JE; Le Chatellier E; Pons N; Galleron N; Roume H; Duong CPM; Mondragón L; Iribarren K; Bonvalet M; Terrisse S; Rauber C; Goubet AG; Daillère R; Lemaitre F; Reni A; Casu B; Alou MT; Alves Costa Silva C; Raoult D; Fizazi K; Escudier B; Kroemer G; Albiges L; Zitvogel L Eur Urol; 2020 Aug; 78(2):195-206. PubMed ID: 32376136 [TBL] [Abstract][Full Text] [Related]
3. Gut Microbiota in Cancer Immune Response and Immunotherapy. Zhou CB; Zhou YL; Fang JY Trends Cancer; 2021 Jul; 7(7):647-660. PubMed ID: 33674230 [TBL] [Abstract][Full Text] [Related]
4. Gut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors. Wang J; Zhu N; Su X; Yang R Cancer Lett; 2024 Feb; 582():216582. PubMed ID: 38065401 [TBL] [Abstract][Full Text] [Related]
5. Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality. Guillot N; Roméo B; Manesh SS; Milano G; Brest P; Zitvogel L; Hofman P; Mograbi B Trends Mol Med; 2023 Nov; 29(11):897-911. PubMed ID: 37704493 [TBL] [Abstract][Full Text] [Related]
6. Probiotics Wang T; Zheng N; Luo Q; Jiang L; He B; Yuan X; Shen L Front Immunol; 2019; 10():1235. PubMed ID: 31214189 [TBL] [Abstract][Full Text] [Related]
7. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. Isaacs J; Anders C; McArthur H; Force J Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085 [TBL] [Abstract][Full Text] [Related]
8. A review of immune checkpoint blockade in breast cancer. Pellegrino B; Tommasi C; Cursio OE; Musolino A; Migliori E; De Silva P; Senevirathne TH; Schena M; Scartozzi M; Farci D; Willard-Gallo K; Solinas C Semin Oncol; 2021 Jun; 48(3):208-225. PubMed ID: 34620502 [TBL] [Abstract][Full Text] [Related]
9. Gut microbiota shed new light on the management of immune-related adverse events. Tan B; Liu YX; Tang H; Chen D; Xu Y; Chen MJ; Li Y; Wang MZ; Qian JM Thorac Cancer; 2022 Oct; 13(19):2681-2691. PubMed ID: 36043345 [TBL] [Abstract][Full Text] [Related]
11. Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy. Joo KI; Jeong Y; Hwang SM; Shin M; Lee J; Sharma G; Lee H; Im SH; Cha HJ Biomaterials; 2020 Dec; 263():120380. PubMed ID: 32942128 [TBL] [Abstract][Full Text] [Related]
12. Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. Zemek RM; Chin WL; Nowak AK; Millward MJ; Lake RA; Lesterhuis WJ Front Immunol; 2020; 11():223. PubMed ID: 32133005 [TBL] [Abstract][Full Text] [Related]
13. Combination immunotherapy strategies for glioblastoma. Chan HY; Choi J; Jackson C; Lim M J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705 [TBL] [Abstract][Full Text] [Related]
14. Harnessing Microbiota to Improve Immunotherapy for Gastrointestinal Cancers. Goc J; Sonnenberg GF Cancer Immunol Res; 2022 Nov; 10(11):1292-1298. PubMed ID: 36166399 [TBL] [Abstract][Full Text] [Related]
15. [The Gut Microbiota Metabolite A Enhances the Anti-Tumor Effects of Anti-PD-1 Antibody Therapy through Immune Modulation]. Hosonuma M; Murayama M; Yoshimura K Gan To Kagaku Ryoho; 2023 Sep; 50(9):960-964. PubMed ID: 37800288 [TBL] [Abstract][Full Text] [Related]
16. Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. Gu Y; Zhang Z; Ten Dijke P Cell Mol Immunol; 2023 Apr; 20(4):318-340. PubMed ID: 36823234 [TBL] [Abstract][Full Text] [Related]
17. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer. Piening A; Ebert E; Khojandi N; Alspach E; Teague RM Front Immunol; 2022; 13():1022732. PubMed ID: 36582225 [TBL] [Abstract][Full Text] [Related]
18. Precision Probiotic Medicine to Improve ICB Immunotherapy. Di Luccia B; Colonna M Cancer Discov; 2022 May; 12(5):1189-1190. PubMed ID: 35491646 [TBL] [Abstract][Full Text] [Related]
19. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Zhou X; Ni Y; Liang X; Lin Y; An B; He X; Zhao X Front Immunol; 2022; 13():915094. PubMed ID: 36189283 [TBL] [Abstract][Full Text] [Related]
20. Gut microbiota: impacts on gastrointestinal cancer immunotherapy. Lau HCH; Sung JJ; Yu J Gut Microbes; 2021; 13(1):1-21. PubMed ID: 33435800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]